FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | Merck | Dynavax | Heplisav | hepatitis B

Merck, Dynavax announce Heplisav results

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed protective antibodies to hepatitis B versus 81.1 percent of subjects who received Engerix-B, a marketed drug. Heplisav is being developed for patients with end-stage renal disease.

Back in April the FDA put a clinical hold on the drug's development because one subject was suspected to have Wegener's granulomatosis, an rare inflammation of blood vessels. The hold is still in effect, and the FDA has requested a review of clinical and preclinical safety data along with all available information about the Wegener's granulomatosis case.

- here's the release

Related Articles:
Dynavax shares hammered on FDA clinical hold
Merck, Dynavax ink $136M deal on hep B therapy
Dynavax pockets $30M to fund new development
Dynavax stock jumps on hep B data
Dynavax Hep B vaccine successful in Phase II


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Heplisav   hepatitis B   Vaccine   Merck   Dynavax  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.